What's in Advenchen Laboratories, LLC's pipeline?

Advenchen Laboratories, LLC has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Advenchen Laboratories, LLC's portfolio?

Top competitors by shared drug class: Meir Medical Center, Nuvation Bio Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/advenchen-laboratories-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Advenchen Laboratories, LLC — Portfolio Competitive Intelligence Brief

Advenchen Laboratories, LLC pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Digoxin (0.25mg)	Digoxin (0.25mg)	phase 3	Cardiac glycoside	Na+/K+-ATPase	Cardiovascular

Therapeutic area mix

Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Meir Medical Center · 1 shared drug class
Nuvation Bio Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Advenchen Laboratories, LLC:

Cite this brief

Drug Landscape (2026). Advenchen Laboratories, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/advenchen-laboratories-llc. Accessed 2026-05-16.